<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/8163D851-26A0-4CAD-9A5E-261DB92BD7AE"><gtr:id>8163D851-26A0-4CAD-9A5E-261DB92BD7AE</gtr:id><gtr:name>Gelexir Healthcare Limited</gtr:name><gtr:address><gtr:line1>THE OBSERVATORY , CHAPEL WALKS</gtr:line1><gtr:city>MANCHESTER</gtr:city><gtr:postCode>M2 1HL</gtr:postCode><gtr:region>North West</gtr:region></gtr:address><gtr:typeInd>P</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/8163D851-26A0-4CAD-9A5E-261DB92BD7AE" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="gtr:organisationParticipantRole"><gtr:id>8163D851-26A0-4CAD-9A5E-261DB92BD7AE</gtr:id><gtr:name>Gelexir Healthcare Limited</gtr:name><gtr:address><gtr:line1>THE OBSERVATORY , CHAPEL WALKS</gtr:line1><gtr:city>MANCHESTER</gtr:city><gtr:postCode>M2 1HL</gtr:postCode><gtr:region>North West</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_PARTICIPANT</gtr:name></gtr:role><gtr:role><gtr:name>PARTICIPANT</gtr:name></gtr:role></gtr:roles><gtr:offerGrant>25000.0</gtr:offerGrant><gtr:projectCost>42000.0</gtr:projectCost></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/7B079523-F73E-45CA-A89D-9E54BF06126E"><gtr:id>7B079523-F73E-45CA-A89D-9E54BF06126E</gtr:id><gtr:firstName>Hans</gtr:firstName><gtr:surname>von Celsing</gtr:surname><gtr:roles><gtr:role><gtr:name>PROJECT_MANAGER</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=700161"><gtr:id>16467DDE-B004-43AC-837B-0E16829B9808</gtr:id><gtr:title>Business Plan for Gelexir Ltd</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>GRD Proof of Market</gtr:grantCategory><gtr:grantReference>700161</gtr:grantReference><gtr:abstractText>The purpose of the project is for the development of a Business Plan and Investment
memorandum for Gelexir Ltd. This will include market assessment and competitive analysis,
business strategy, regulatory approval plan, IP review as well as product development and
testing plan. The Plan will be used for raising sufficient funds from institutional and private
investors. These funds will be used for the implementation of; the clinical trials program,
regulatory approval plan and necessary working capital taking the company to a commercial
launch stage. The market is huge as Chronic lower back pain (CLBP) affects 55m people in
the Western World and costs society many billions of &amp;pound;. The scientific founders are Professor
Anthony Freemont, and Professor Brian Saunders at the University of Manchester.</gtr:abstractText><gtr:fund><gtr:end>2013-02-28</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/E18E2F0F-AC7D-4E02-9559-669F7C8FEC74"><gtr:id>E18E2F0F-AC7D-4E02-9559-669F7C8FEC74</gtr:id><gtr:name>Innovate UK</gtr:name></gtr:funder><gtr:start>2012-10-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>25000</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications/><gtr:identifiers><gtr:identifier type="RCUK">700161</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>